CagriSema

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Type 2 DiabetesObesityPeripheral NeuropathyWeight LossDiabetes Mellitus, Type 2

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

1

CagriSema

Novo Nordisk

Phase 3

12

Jardiance

Boehringer Ingelheim

Preclinical

313

Glargine

Eli Lilly

Preclinical

84

Aurlumyn

BBTG International Inc.

Preclinical

15

Cecon

MMcGuff Pharmaceuticals, Inc.

Preclinical

16

Forxiga

AstraZeneca

Preclinical

37

Sulfonylureas

Eli Lilly

Preclinical

18

Acipimox

Boehringer Ingelheim

Preclinical

29

Henagliflozin

TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Preclinical

110

Antiplatelet Drug

FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Preclinical

1Show 12 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Weight loss2 trials

A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet

Recruiting·Novo Nordisk·Phase 1·NCT07184086·80 enrolled

A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term

Active, not recruiting·Novo Nordisk·Phase 3·NCT07011667·609 enrolled

Obesity2 trials

A Placebo-controlled Comparability Study to Compare Two Presentations of CagriSema in Participants With Overweight or Obesity

Withdrawn·Novo Nordisk·Phase 3·NCT07357766

A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity With or Without Type 2 Diabetes

Recruiting·Novo Nordisk·Phase 3·NCT07564414·2,500 enrolled

Type 2 Diabetes1 trial

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes

Not yet recruiting·Novo Nordisk·Phase 3·NCT07282613·80 enrolled

Peripheral Neuropathy1 trial

A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy

Active, not recruiting·Novo Nordisk·Phase 2·NCT06797869·142 enrolled

Overweight1 trial

A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity

Completed·Novo Nordisk·Phase 1·NCT06716307·18 enrolled

1 more indication

Diabetes Mellitus, Type 21 trial

A Phase 2 Study to Compare Two Presentations of CagriSema in Participants With Type 2 Diabetes

Withdrawn·Novo Nordisk·Phase 2·NCT07357740

Details

Drug Info

Related News